Dinari specializes in global employee stock options management. It offers comprehensive services including equity management, options grants, payroll compliance, taxes, and vesting schedules.
Toku operates an online financial platform designed for B2C companies, focusing on the automation of collections and streamlining the payment process. The platform leverages machine learning to optimize the collection of recurring payments, thereby reducing late payments and enhancing operational efficiency. Toku also provides features that allow companies to manage automatic payment methods, including inactivation and deactivation. By facilitating payment orchestration and offering account-to-account payments, Toku aims to lower payment fees and improve the overall financial operations of its clients.
Galatea Bio
Venture Round in 2025
Galatea Bio is a biotechnology company based in the United States, founded by Carlos Bustamante, Nicholas Katsanis, and Alexander Ioannidis. The company focuses on improving diagnostic testing and accelerating drug discovery specifically for diverse and underserved populations that have historically been underrepresented in genetics research. Galatea Bio operates a biobank that serves as a biosample and bioinformatics platform, utilizing advanced algorithms and innovative analyses to facilitate genomic discoveries. Through its world-class clinical network, the company aims to identify patients at risk for severe multi-inflammatory syndromes or infections, ultimately working to develop new tests, treatments, and cures that enhance healthcare outcomes for all.
Bluebird Kids Health
Series A in 2025
Bluebird Kids Health is a pediatric healthcare provider that aims to build a healthier future for children. It offers a value-based care model, delivering comprehensive, evidence-based care tailored to each family's needs. Services include nutrition support, sleep training, treatments for common ailments like rashes and viruses, all aimed at reducing medical costs and providing personalized care. The company is also developing a proprietary technology platform, enhanced by AI, to proactively manage and coordinate treatment, further simplifying the experience for its clinical team.
Ethena
Funding Round in 2025
Ethena provides derivative infrastructure in order to transform Ethereum into the first crypto-native yield bearing stablecoin.
Eleos Health
Series C in 2025
Eleos Health offers automated healthcare technology solutions. Its AI-powered Speech-to-Insights system aids clinicians in making decisions swiftly, ensuring personalized, efficient, and cost-effective patient care.
Rhygaze is a biotechnology company focused on developing innovative gene therapies aimed at restoring vision in individuals affected by blindness-related diseases. The company’s therapy utilizes advanced technology to deliver a light-sensor gene directly to cone cells that have lost their light sensitivity. By repairing these cells' ability to detect light, Rhygaze seeks to enable effective vision restoration for patients. Through its specialized approach, the company aims to make significant contributions to the healthcare industry and improve the quality of life for those facing vision loss.
Tenvie Therapeutics
Series A in 2025
Tenvie Therapeutics is a biotechnology company founded to improve patients' lives with neurological, cardiometabolic, and ophthalmic diseases. The company is focused on developing small molecules targeting brain inflammation, metabolic dysfunction, and lysosomal issues, with a robust pipeline inherited from Denali Therapeutics. Tenvie is progressing a range of therapeutics aimed at addressing neurological, cardiometabolic, and ophthalmic conditions. Its collection of fully owned, highly brain-penetrant, and precisely designed peripherally restricted small molecules targets three main factors of disease: alleviating inflammation, correcting metabolic dysfunction, and rejuvenating lysosomal function.
TripSuite
Seed Round in 2024
TripSuite is a venture-backed Software as a Service (SaaS) company dedicated to supporting travel agencies. It aims to facilitate broader access to travel experiences by streamlining payment processes for travel professionals. TripSuite's platform generates supplier invoices, automatically matches payments, resolves unknown commissions, and manages revenue, enabling agencies to run their business more efficiently.
Tenpoint Therapeutics
Venture Round in 2024
Tenpoint Therapeutics is a biotechnology company dedicated to developing engineered cell-based therapies aimed at restoring vision for individuals affected by degenerative ocular diseases. The company leverages an innovative platform that includes in vivo reprogramming techniques, allowing for targeted delivery of therapeutic systems directly to the eye. This approach eliminates the need for systemic administration, which can improve treatment efficacy and patient outcomes. By focusing on vision restoration, Tenpoint Therapeutics strives to significantly enhance the quality of life for patients suffering from various eye conditions.
Albert Invent
Series A in 2024
Albert Invent offers an end-to-end platform that integrates electronic lab notebooks, laboratory information management systems, and AI tools for modern materials science R&D. The platform enhances collaboration, data management, and regulatory compliance while accelerating innovation in chemical research.
Laurus Bio
Venture Round in 2024
Laurus Bio specializes in precision fermentation services, focusing on microbial fermentation-based manufacturing and product development. They produce animal-origin-free recombinant proteins, growth factors, and cell-culture media supplements, catering to industries such as cultured meat, biologics manufacturing, vaccines, stem cells, and regenerative medicine.
Teleo specializes in transforming existing heavy machinery into remote-controlled robots, allowing operators to control equipment from a significant distance. By retrofitting current fleets with its advanced supervised autonomy technology, Teleo enables operators to seamlessly switch between machines and job sites, enhancing both productivity and safety. The company's approach allows machine operators to work from remote operation centers rather than being confined to the equipment's cabin, ultimately improving operational efficiency and providing valuable insights into job site conditions.
Lighthouse
Series C in 2024
Lighthouse is a commercial platform tailored for the travel and hospitality industry, specializing in hotel management solutions. The company offers a cloud-based platform that visualizes and leverages data to enhance business success. By providing actionable market insights and business intelligence tools, Lighthouse enables hoteliers and hotel management companies to make informed revenue and distribution decisions. Its services include real-time data analytics, which empower users to maximize property occupancy rates and increase revenue and profit. Formerly known as OTA Insight, Lighthouse aims to transform complex market dynamics into manageable strategies that foster growth in the hospitality sector.
Founded in 2014 by Stanford University Biodesign Fellows collaborating with leading urologists, Zenflow develops a novel spring device to alleviate permanent benign prostatic hyperplasia (BPH) symptoms in men. Its minimally invasive solution preserves natural anatomy and improves patient experience.
Notabene, Inc. is a New York-based company founded in 2020 that specializes in developing a software as a service (SaaS) platform for crypto compliance tailored for the financial industry. The company focuses on helping financial institutions adhere to emerging global regulations concerning cryptocurrency transactions, specifically addressing the complexities of the Travel Rule. Notabene offers a unified API and dashboard designed to assist compliance officers in managing risk associated with both Travel Rule and non-custodial transactions. By providing access to a broad network of crypto businesses, Notabene simplifies the compliance process, enhances transaction confidence, and ultimately supports its clients in increasing their transaction volumes and business growth.
Based on our deep science and focused on patients in need.
Shift Bioscience
Seed Round in 2024
Shift Bioscience employs simulation-guided techniques to identify safer gene factors for cellular rejuvenation, aiming to develop a drug family that treats multiple age-related diseases. Its high-throughput aging biomarker enables accurate cell simulations, with the goal of making full health in old age accessible via prescription.
Iglu is a software development company that facilitates sales automation by connecting e-commerce platforms with physical stores. It offers multiple payment methods and integrates with ERP systems.
Spry is a digital health platform that enables movement health professionals to collect and analyze patient data in real time. By leveraging machine learning and artificial intelligence, the platform provides personalized protocols based on evidence-based practices and standards of care. This allows practitioners and owners of physical therapy centers to effectively manage both clinical and administrative functions, enhancing the quality of patient care and operational efficiency.
Rippl Care
Series A in 2024
Rippl Care is a mental health company based in Seattle, Washington, dedicated to supporting seniors experiencing dementia and other neurocognitive disorders. Founded in 2021, the company employs a value-based approach and innovative technology to deliver comprehensive care tailored to individual needs. By prioritizing the empowerment of its clinicians, Rippl Care adopts a novel care model that enables seniors to receive personalized support through various channels, including phone, online, and in-home visits. This commitment to enhancing the quality of care for those affected by neurocognitive conditions sets Rippl Care apart in the mental health landscape.
Centivo
Venture Round in 2024
Centivo Corporation is a health insurance provider that specializes in offering innovative health plans for self-funded employers, employees, and clinicians. Established in 2016 and headquartered in Stamford, Connecticut, with additional offices in New York and Buffalo, Centivo serves as an alternative to traditional insurance carriers and third-party administrators. The company integrates technology, network management, claims processing, and customer support to effectively administer health benefits. Centivo emphasizes collaboration between employees and their primary care teams to coordinate healthcare needs, encouraging members to engage in high-value care through personalized matching tools and a user-friendly app. By focusing on controlling costs and improving navigation through the healthcare system, Centivo positions itself as a dedicated partner to employers, ensuring accountability and minimizing waste in healthcare spending.
Space and Time
Series A in 2024
Space and Time is a decentralized analytics platform designed to facilitate low-latency queries and tamperproof analytics across the Web. The company provides a multichain data solution tailored for decentralized applications (dapps) and developers in sectors such as gaming and decentralized finance (DeFi). Its platform enables the integration of on-chain and off-chain data, allowing users to perform complex analytics in a single query. By transforming major blockchains into advanced databases, Space and Time empowers organizations to achieve enterprise-scale analytics while enhancing the speed and reliability of their data operations.
Canoe Software Inc. provides a sophisticated software solution focused on financial document and data management. Founded in 2013 and based in New York, the company specializes in automating the extraction and organization of investment documents using artificial intelligence and machine learning technologies. This enables users to efficiently convert unstructured data from various formats, such as PDFs, into actionable insights, thereby improving operational efficiency. Canoe's platform supports a wide range of clients, including single and multi-family offices, endowments, foundations, pensions, investment consultants, and financial institutions, facilitating better management of post-investment operations, monitoring, and reporting. By streamlining the data management process, Canoe helps minimize manual data entry and enhances the accuracy of financial reporting and analysis.
RareCyte
Venture Round in 2024
RareCyte, Inc. is a life sciences company based in Seattle, Washington, founded in 2009. The company specializes in developing advanced platforms for liquid and tissue biopsy analysis, focusing on the detection and characterization of rare cells, particularly circulating tumor cells (CTCs) and circulating endothelial cells (CECs) in blood samples. RareCyte's AccuCyte system provides an open platform that facilitates the unbiased discovery and isolation of these rare cells, supporting various applications in cancer research, cardiovascular disease studies, and diagnostic development. The company offers a range of products, including sample preparation systems, staining kits, automated fluorescence microscopy instruments, and slide imaging systems. By enabling precision medicine approaches, RareCyte aims to provide new tools for medical professionals and researchers to address complex questions in the fields of cancer and other therapeutic areas.
Odaseva is a company specializing in data management solutions for large enterprises utilizing Salesforce. It offers a comprehensive cloud-based platform that focuses on data protection, privacy, and governance. The Odaseva Enterprise Data Security Platform is designed to ensure the confidentiality, integrity, and availability of critical business information by providing integrated security products and services. Key features of the platform include backup and recovery, archiving, monitoring of governor limits, and compliance support for regulations such as GDPR. By enabling businesses to take full control of their data, Odaseva helps eliminate risks and facilitates confident digital transformation.
Canary Technologies
Series C in 2024
Canary Technologies is a hospitality technology company that modernizes hotel operations. It offers a guest management platform featuring contactless check-in, digital authorizations, and an amenity store. The platform drives revenue growth, improves staff productivity, ensures compliance, and reduces fraud.
Amber Therapeutics
Series A in 2024
Amber Therapeutics specializes in developing advanced bioelectronic therapies that can sense and adapt, aiming to enhance clinical outcomes for patients with functional disorders of the peripheral nervous system.
Ashby is a developer of recruitment software tailored for high-growth companies. The company creates enterprise-grade employment solutions designed to enhance the hiring processes of organizations. Its platform enables company leaders, recruiters, and hiring managers to streamline their recruitment efforts, thereby improving overall efficiency and productivity. Ashby's software is accessible for teams of various sizes, allowing them to effectively meet their hiring objectives while fostering organizational growth.
Expressable
Series B in 2024
Expressable is an online speech therapy practice dedicated to enhancing communication for individuals with speech and language disorders. It employs a parent-focused care model that integrates technology and educational resources, allowing families to incorporate speech therapy techniques into their daily routines. The platform offers a range of services, including support for accent modification, aphasia, apraxia of speech, autism spectrum disorder, and various language disorders. By providing tailored weekly practice activities, Expressable aims to improve speech and language outcomes for both children and adults, ensuring a more effective and accessible therapy experience.
Quantum Circuits
Venture Round in 2024
Founded in 2015 by Dr. Robert Schoelkopf, Quantum Circuits develops and manufactures quantum computers based on superconducting devices. The company focuses on creating full-stack quantum computers designed for efficient scaling, with a pioneering approach to error detection and correction.
Xaira Therapeutics
Venture Round in 2024
Xaira Therapeutics is a biotechnology company that leverages artificial intelligence to revolutionize drug discovery and development. Headquartered in the San Francisco Bay Area, Xaira brings together machine learning experts, expansive data generation, and robust therapeutic product development to advance treatments for various diseases.
Metsera is a clinical-stage biopharmaceutical company specializing in developing innovative therapies for obesity and metabolic conditions. It focuses on advancing oral and injectable treatments, integrating proprietary health technology tools for personalized care.
Toku operates an online financial platform designed for B2C companies, focusing on the automation of collections and streamlining the payment process. The platform leverages machine learning to optimize the collection of recurring payments, thereby reducing late payments and enhancing operational efficiency. Toku also provides features that allow companies to manage automatic payment methods, including inactivation and deactivation. By facilitating payment orchestration and offering account-to-account payments, Toku aims to lower payment fees and improve the overall financial operations of its clients.
Teleo specializes in transforming existing heavy machinery into remote-controlled robots, allowing operators to control equipment from a significant distance. By retrofitting current fleets with its advanced supervised autonomy technology, Teleo enables operators to seamlessly switch between machines and job sites, enhancing both productivity and safety. The company's approach allows machine operators to work from remote operation centers rather than being confined to the equipment's cabin, ultimately improving operational efficiency and providing valuable insights into job site conditions.
Engrail Therapeutics
Series B in 2024
Founded in 2019, Engrail Therapeutics is dedicated to developing and commercializing neuro drugs. Its primary focus is on treating diseases related to the nervous system. The company's flagship compound, ENX-101, is a preclinical modulator of a receptor for GABA, a neurotransmitter in the brain.
HiLabs is a developer of a healthcare data mining platform that aims to enhance data-driven decision-making within healthcare organizations. By leveraging artificial intelligence, HiLabs empowers employees to explore their data intuitively, uncover novel insights, and interact with data visualizations. The platform allows users to customize dashboards and generate new attributes, thus enhancing their ability to understand and utilize client health data effectively. HiLabs recognizes that healthcare providers possess vital domain knowledge but often lack the necessary tools to extract meaningful insights from their data. Through its innovative solutions, HiLabs bridges this gap, enabling healthcare organizations to harness their data more efficiently and improve overall decision-making processes.
Nocion Therapeutics
Series B in 2024
Nocion Therapeutics is a biopharmaceutical company developing novel therapies called 'nocions' that selectively target actively firing nociceptors to provide relief for serious conditions such as cough, itch, pain, and inflammation.
Comanche Biopharma
Series B in 2024
Comanche is a biopharmaceutical company developing an investigational siRNA medicine for preterm preeclampsia. Its mission is to provide safe, effective, evidence-based, and affordable therapies for treating life-threatening complications of pregnancy.
Dispatch
Seed Round in 2024
Dispatch helps independent financial advisors to build ideal firms through strategic investments and advanced technology.
Burro is a developer of an autonomous farming platform designed to enhance productivity in agricultural and outdoor settings. The company creates robotic tools that autonomously follow workers and transport cargo, alleviating the physical burden of labor-intensive tasks. By automating these processes, Burro allows farmworkers to concentrate on more value-added activities. Additionally, the company's technology captures essential data that aids in further automating farm operations, ultimately aiming to streamline all tedious agricultural tasks. This focus on operational efficiency not only supports farmers in improving their workflows but also fosters growth within the sector.
Founded in 2014, Genomics develops algorithms and software solutions focused on cancer, microbes, and rare diseases. Its solutions empower governments, healthcare providers, pharmaceutical companies, clinicians, and researchers to improve diagnoses, treatment options, and drug development processes through accurate genomic data analysis.
OnCusp Therapeutics
Series A in 2024
OnCusp Therapeutics is a biopharmaceutical company dedicated to accelerating oncology medication innovation globally. It focuses on translating preclinical drug candidates into clinical proof-of-concept stage and advancing them for rapid global early clinical development.
Devoted Health
Series E in 2023
Founded in 2017, Devoted Health is dedicated to enhancing the health and well-being of older Americans by offering integrated Medicare Advantage plans. They provide personalized care through a combination of local providers, virtual and in-home care, dedicated guides, and advanced technology.
PlasmaGen Biosciences
Venture Round in 2023
PlasmaGen Biosciences Pvt. Ltd., established in 2010 and based in Bengaluru, India, is a biopharmaceutical company specializing in plasma protein therapies. The company manufactures a range of products including PlasmaGlob and AlbuMax, brands of Normal Human Immunoglobulin for Intravenous use, PlasmaRho-D I.V. for Rh immunization suppression, PlasmaRAB for rabies infection prophylaxis, PlasmaHep for hepatitis B exposure, VerBumin for conditions like hypovolemic shock and burns, and Gammafact-VIII. These products cater to various medical fields such as hematology, oncology, immunology, pediatrics, rheumatology, dermatology, and neurology. The company serves clinicians, medical practitioners, corporate hospitals, and government institutions.
Shinobi Therapeutics
Series A in 2023
Shinobi Therapeutics is a biotechnology company dedicated to developing innovative cell therapies that utilize hypoimmune CD8αβ induced pluripotent stem cells (iPS-T cells) to enhance cancer treatment and address other diseases. The company's advanced immune evasion technology aims to improve the effectiveness and accessibility of these therapies, ultimately reducing costs and enhancing patient outcomes. By focusing on durable responses and the potential for redosing, Shinobi Therapeutics strives to provide the healthcare industry with comprehensive immune therapies that can address a range of diseases, including cancer and genetic disorders.
ARTBIO is a biotechnology company developing a new class of alpha radioligand medicines for cancer treatment. It focuses on radioligand therapy, delivering alpha or beta emitters to target and destroy cancer cells.
T-Therapeutics
Series A in 2023
T-Therapeutics is a biopharmaceutical company focused on developing engineered soluble biologics for oncological and immunological applications. The company utilizes a proprietary T cell receptor (TCR) discovery platform based on a highly humanized mouse model, which allows access to TCRs for human antigens that are typically unavailable from human samples. This innovative approach enables the binding of specific peptide-MHC (pMHC) targets on cells, facilitating the recruitment of T cells to combat cancer or modulate immune responses. Through its advanced capabilities in mouse genome engineering, single-cell genomics, machine learning, and structural biology, T-Therapeutics aims to enhance the quality of life for patients suffering from chronic and infectious diseases. The company's culture emphasizes creativity and collaboration, fostering an environment conducive to groundbreaking research and development in the biopharmaceutical field.
Eleos Health
Series B in 2023
Eleos Health offers automated healthcare technology solutions. Its AI-powered Speech-to-Insights system aids clinicians in making decisions swiftly, ensuring personalized, efficient, and cost-effective patient care.
Founded in 2019, Warmly develops an autonomous revenue orchestration platform tailored for small and mid-sized revenue teams. Its software aggregates metadata from sales enablement tools, B2B intent data, and enrichment tools to identify and connect with website visitors ready to convert, driving qualified conversations for the sales team.
Doceree is a healthcare marketing technology company that provides a platform and solutions to help pharmaceutical and healthcare brands reach healthcare professionals. Its programmatic platform supports physician engagement and targeted advertising across physician networks, medical journals, telemedicine platforms, and relevant digital channels, delivering compliant, scalable messages. The platform uses artificial intelligence, data segmentation, and analytics to identify target healthcare professionals and optimize reach across global digital ecosystems. Doceree serves pharmaceutical brands, medical device brands, consumer health brands, hospitals, and media agencies, enabling access to physician-only environments and enabling compliant engagement at scale.
Adela specializes in developing innovative technologies for early detection of high-morbidity conditions like cancer through routine blood tests. Its proprietary platform efficiently captures and analyzes the methylome, focusing on highly informative regions to enhance diagnostic accuracy.
Nvelop Therapeutics
Seed Round in 2023
Nvelop Therapeutics develops programmable delivery systems for in vivo gene editing and therapeutic cargo delivery. It combines epigenetic editing technologies with next-generation delivery methods to address unmet medical needs. The company focuses on genetic medicines designed to target cells and tissues within the body, aiming to treat severe genetic diseases by delivering gene-editing payloads to therapeutically relevant sites. Early efforts are aligned with enabling editing in cells and tissues that have been difficult to reach, with the objective of expanding the range of actionable genetic therapies. The company seeks to advance in vivo approaches that can improve precision and safety in delivering therapeutic cargo to patients.
Better Life Partners
Series B in 2023
Better Life Partners Inc. is a healthcare company based in Hanover, New Hampshire, dedicated to providing comprehensive support for individuals struggling with opioid use disorder in the United States. Established in 2018, the company offers a range of services, including medication-assisted treatment, counseling, peer coaching, and group sessions. Better Life Partners focuses on delivering personalized healthcare to vulnerable populations, utilizing technology to create customizable care plans that ensure effective and reliable service delivery. By integrating medical and behavioral healthcare, the company addresses the needs of those affected by addiction, facilitating their recovery through a combination of telehealth, community-based support, and innovative care approaches. With additional offices across New Hampshire, Better Life Partners aims to make a meaningful impact on the lives of individuals seeking to overcome substance abuse challenges.
Simon Data
Series D in 2023
Simon Data develops a customer data platform designed to enhance campaign performance via precise segmentation and personalization. Its platform identifies purchase intent, predicts churn, estimates customer lifetime value, and enables brands to deliver personalized experiences across channels.
Tenpoint Therapeutics
Series A in 2023
Tenpoint Therapeutics is a biotechnology company dedicated to developing engineered cell-based therapies aimed at restoring vision for individuals affected by degenerative ocular diseases. The company leverages an innovative platform that includes in vivo reprogramming techniques, allowing for targeted delivery of therapeutic systems directly to the eye. This approach eliminates the need for systemic administration, which can improve treatment efficacy and patient outcomes. By focusing on vision restoration, Tenpoint Therapeutics strives to significantly enhance the quality of life for patients suffering from various eye conditions.
K36 Therapeutics
Series B in 2023
K36 Therapeutics develops small molecule therapeutics for cancer treatment. It translates epigenetic modulation of oncogenic pathways into small molecule therapies.
ARTBIO is a biotechnology company developing a new class of alpha radioligand medicines for cancer treatment. It focuses on radioligand therapy, delivering alpha or beta emitters to target and destroy cancer cells.
Albert Invent
Seed Round in 2023
Albert Invent offers an end-to-end platform that integrates electronic lab notebooks, laboratory information management systems, and AI tools for modern materials science R&D. The platform enhances collaboration, data management, and regulatory compliance while accelerating innovation in chemical research.
BenchSci is a developer of a research intelligence platform that leverages artificial intelligence and machine learning to enhance the efficiency of biomedical research. The company's technology translates both closed and open-access data into actionable recommendations for specific experiments, particularly in antibody extraction. By streamlining the experimental process, BenchSci allows researchers and scientists to conduct successful experiments more quickly and with reduced resource wastage. The platform is utilized by pharmaceutical companies and over 4,300 research centers globally, significantly contributing to the acceleration of drug discovery and biomedical advancements.
BTP Automation
Grant in 2023
BTP Automation provides a hotel sourcing platform and analytics for corporate travel programs. The company collects and analyzes booking and hotel data from multiple sources to generate automated cost savings and to provide insights into hotel attachment rates. Its platform supports corporate travel program management by gathering booking details, applying machine learning for instant adjustments, and streamlining contract term negotiations across the hotel program lifecycle. This enables travel managers to achieve measurable cost reductions while reducing administrative effort and maintaining transparency on policy compliance and accommodation spend.
Comanche Biopharma
Venture Round in 2023
Comanche is a biopharmaceutical company developing an investigational siRNA medicine for preterm preeclampsia. Its mission is to provide safe, effective, evidence-based, and affordable therapies for treating life-threatening complications of pregnancy.
Adcentrx Therapeutics
Series A in 2023
Adcentrx Therapeutics is a biotechnology company focused on protein conjugate therapeutics for cancer and other life-threatening diseases. The company seeks to accelerate breakthroughs in this field by combining the targeting precision of biologics with the potency of small-molecule payloads, enabling next-generation targeted therapies and expanding treatment options for patients.
Founded in 2014, Tradier operates a cloud-based financial services platform. It offers APIs, modules, and tools for platform providers, developers, and investors, enabling improved trade execution, real-time market data access, and transparent pricing.
1upHealth
Series C in 2023
Founded in 2017, 1upHealth operates a health data aggregation platform that securely centralizes patient records from various electronic medical systems. Its platform enables patients to control and share their consolidated digital health record with providers, while also allowing developers to access clinical data from connected clinics and hospitals.
SpectrumAi
Series A in 2023
SpectrumAi is a digital health company focused on enhancing Autism care by increasing access to high-quality Applied Behavior Analysis (ABA) therapy for children globally. By collaborating with industry experts in technology and healthcare, as well as clinical leaders, parents, and payers, SpectrumAi aims to modernize the delivery of autism care. The company's innovative healthcare technology offers objective data, meaningful insights, and actionable recommendations, all designed to support patients in achieving optimal outcomes. These outcomes include fostering independent living, building meaningful relationships, pursuing lifelong vocational goals, and promoting self-advocacy. Through its efforts, SpectrumAi seeks to transform the landscape of autism treatment and improve the quality of life for individuals on the spectrum.
Zus Health
Series A in 2023
Zus Health is a healthcare technology company founded in 2020 by Jonathan Bush, based in Watertown, Massachusetts. It specializes in developing a healthcare data platform that accelerates the creation of digital health solutions. The platform uniquely integrates health and non-health information, allowing healthcare professionals to gain a comprehensive understanding of patients while sharing clinical and non-clinical data without requiring the same applications. By removing traditional barriers, Zus Health empowers a new generation of healthcare builders to design technologies and services that are more affordable and customizable, aiming to enhance the overall healthcare experience.
Toku operates an online financial platform designed for B2C companies, focusing on the automation of collections and streamlining the payment process. The platform leverages machine learning to optimize the collection of recurring payments, thereby reducing late payments and enhancing operational efficiency. Toku also provides features that allow companies to manage automatic payment methods, including inactivation and deactivation. By facilitating payment orchestration and offering account-to-account payments, Toku aims to lower payment fees and improve the overall financial operations of its clients.
TandemAI is an advanced technology company dedicated to reinventing drug discovery infrastructure. The company integrates proprietary AI-driven, high-performance computation with its efficient, large-scale in-house wet lab operations to deliver a turnkey drug discovery solution.
Cadence Neuroscience
Venture Round in 2023
Cadence Neuroscience develops implantable medical device therapies for epilepsy, central pain, and other neurological disorders. Founded in 2017 and based in Redmond, Washington, the company pursues core technology developed at Mayo Clinic that is being evaluated clinically. The device detects brain signals and delivers electrical stimulation to modulate neural circuits, enabling personalized brain stimulation to improve seizure control relative to existing protocols.
Canoe Software Inc. provides a sophisticated software solution focused on financial document and data management. Founded in 2013 and based in New York, the company specializes in automating the extraction and organization of investment documents using artificial intelligence and machine learning technologies. This enables users to efficiently convert unstructured data from various formats, such as PDFs, into actionable insights, thereby improving operational efficiency. Canoe's platform supports a wide range of clients, including single and multi-family offices, endowments, foundations, pensions, investment consultants, and financial institutions, facilitating better management of post-investment operations, monitoring, and reporting. By streamlining the data management process, Canoe helps minimize manual data entry and enhances the accuracy of financial reporting and analysis.
NOCD Inc. is a Chicago-based company founded in 2014 that specializes in developing a mobile application aimed at assisting individuals with obsessive-compulsive disorder (OCD). The platform connects users to licensed therapists who specialize in OCD through face-to-face video therapy sessions. Utilizing cognitive behavioral therapy techniques, the application guides users in self-treatment and monitoring of their symptoms, offering tools for exposure and response prevention exercises. In addition to therapy sessions, NOCD provides 24/7 support via self-help resources and peer communities, facilitating ongoing care and enabling patients to manage their condition effectively. The company focuses on improving treatment outcomes for OCD through its innovative online platform.
Enzene Biosciences
Venture Round in 2023
Enzene Biosciences develops cost-effective biosimilars through advanced analytics and state-of-the-art manufacturing. It aims to provide affordable medicines swiftly, utilizing good manufacturing practices (GMP) processes.
Paradigm is rebuilding the clinical research ecosystem by developing a platform that allows all patients equitable access to trials while improving trial efficiency and lowering barriers to participation for healthcare providers. It is an innovative company that is dedicated to transforming the clinical research ecosystem. Their mission is to create a more accessible and equitable healthcare system by developing a platform that enables patients from diverse backgrounds to participate in clinical trials.
Clinical trials are essential for testing and developing new drugs, therapies, and medical devices, but historically, they have been plagued by inefficiencies, barriers to access, and inequities in patient representation. Paradigm aims to solve these challenges by creating a platform that uses technology and data-driven insights to streamline the clinical trial process, making it more efficient, cost-effective, and inclusive.
The Paradigm platform is designed to facilitate seamless communication and collaboration among all stakeholders involved in clinical research, including patients, healthcare providers, pharmaceutical companies, and regulatory agencies. By leveraging technology such as AI, machine learning, and predictive analytics, Paradigm can identify and match eligible patients to clinical trials, streamline the recruitment and enrollment process, and provide real-time data insights to all stakeholders.
Overall, Paradigm's innovative approach to clinical research has the potential to revolutionize the healthcare industry by improving patient outcomes, reducing healthcare costs, and accelerating the development of new treatments and therapies.
Ensoma is a biotechnology company focused on advancing genomic medicine through its innovative in vivo approach, utilizing proprietary Engenious vectors. These vectors are engineered to deliver a wide array of gene modification technologies directly to blood and immune cells, including T cells, B cells, and myeloid cells, without the necessity for stem cell collection or prior myeloablative conditioning, which can pose risks to patients. This unique method allows for the administration of therapies via a single injection, enhancing accessibility and convenience in various healthcare settings, even where resources may be limited. Ensoma aims to expand the curative potential of genomic medicine, making it more accessible to patients in need.
Alternative Bio
Seed Round in 2022
Alternative Bio is a biotechnology company focused on developing novel therapeutics targeting a previously untapped class of post-translational modifying enzymes.
ABK Biomedical
Series C in 2022
Founded in 2012, ABK Biomedical specializes in developing embolotherapeutic products for treating hypervascular tumors. Its primary focus is improving treatment options for patients through innovative microsphere technology.
Pulmocide
Series C in 2022
Founded in London in 2007, Pulmocide specializes in developing inhaled medicines targeting serious viral and fungal respiratory infections. Its focus is on creating drugs optimized for lung delivery to maximize efficacy while minimizing systemic exposure.
Firefly Health
Venture Round in 2022
Founded in 2016, Firefly Health delivers AI-driven virtual-first primary care. Its platform connects patients with healthcare professionals for convenient, continuous care, focusing on common conditions and women's health issues.
Deal Engine
Seed Round in 2022
Deal Engine LLC is a travel software company founded in 2017 and based in San Francisco, California. The company specializes in providing innovative software solutions that leverage artificial intelligence and application programming interfaces to automate processes traditionally handled by large teams within the travel industry. By utilizing proprietary search and booking algorithms, Deal Engine aims to enhance corporate travel management and reduce travel expenditures by capitalizing on fluctuating pricing. Its platform facilitates digital transformation in the travel sector, allowing corporate travelers and firms to focus on more value-generating activities by eliminating manual processes.
Canary Technologies
Series B in 2022
Canary Technologies is a hospitality technology company that modernizes hotel operations. It offers a guest management platform featuring contactless check-in, digital authorizations, and an amenity store. The platform drives revenue growth, improves staff productivity, ensures compliance, and reduces fraud.
ConnexPay
Private Equity Round in 2022
ConnexPay LLC is a payment solutions provider based in Bonita Springs, Florida, specializing in the travel and e-commerce sectors. Founded in 2017, the company offers an innovative platform that issues single-use virtual credit cards, enabling internet merchants to accept customer payments efficiently. ConnexPay's technology aims to lower the costs associated with card acceptance, eliminate the need for large merchant reserves, and simplify transaction reconciliation. By utilizing real-time payments linked to suppliers, ConnexPay allows clients to reduce their reliance on substantial lines of credit or personal guarantees. The platform incorporates robust anti-fraud measures and is PCI-certified, ensuring secure payment processing. Through a unified solution and straightforward contractual agreements, ConnexPay streamlines the payment acceptance and issuance process for its clients, making it a valuable partner for businesses in the travel and e-commerce industries.
Neumora Therapeutics
Series B in 2022
Neumora Therapeutics is a clinical-stage biotechnology company focused on developing precision medicines for brain diseases by combining data science with neuroscience. Founded to address the global brain disease crisis, Neumora takes an innovative approach to treatment development. The company has established a robust therapeutic pipeline that includes seven clinical and preclinical neuroscience programs targeting novel mechanisms of action for various underserved neuropsychiatric and neurodegenerative disorders. Neumora plans to advance its pipeline further by initiating multiple clinical trials across its programs in the upcoming 12 to 18 months.
Rippl Care
Seed Round in 2022
Rippl Care is a mental health company based in Seattle, Washington, dedicated to supporting seniors experiencing dementia and other neurocognitive disorders. Founded in 2021, the company employs a value-based approach and innovative technology to deliver comprehensive care tailored to individual needs. By prioritizing the empowerment of its clinicians, Rippl Care adopts a novel care model that enables seniors to receive personalized support through various channels, including phone, online, and in-home visits. This commitment to enhancing the quality of care for those affected by neurocognitive conditions sets Rippl Care apart in the mental health landscape.
Elucidata
Series A in 2022
Elucidata Corporation, established in 2015 and based in New Delhi, India, specializes in accelerating drug discovery by translating phenotypic screenings into therapeutic strategies. The company's core offering is Polly, a proprietary SaaS platform that transforms drug discovery through curated biomedical molecular data. Polly hosts over 230,000 multi-omic datasets, with around 50,000 new datasets added monthly, and offers exclusive access to curated data ready for machine learning workflows. This platform enables 10x faster identification of therapeutic assets and has facilitated the detection of multiple validated drug targets across immunology, oncology, and metabolomic disorders. Polly supports discovery programs at prominent biopharma companies such as Pfizer, Agios Pharmaceuticals, Genentech, and Yale, with over 35 research partners from premier institutions.
RIGImmune
Funding Round in 2022
RIGImmune is a biopharmaceutical company dedicated to developing innovative immune-modulating therapies targeting RNA virus diseases and enhancing antitumor immune responses. The company focuses on creating novel treatments aimed at addressing a wide range of conditions associated with viral infections and certain cancers. Its therapeutic candidates are designed to improve treatment outcomes for viral respiratory infections, serving as adjuvants or boosters for healthcare providers. By advancing its research and development efforts, RIGImmune aims to contribute significantly to the treatment landscape for both viral and oncological diseases.
Seis is an online banking platform that caters primarily to Spanish-speaking users in the United States. It offers a range of services including prepaid cards for offline and online purchases, bill payments, money transfers, customizable cards, and video or chat-based customer support.
Hone
Venture Round in 2022
Hone Group Inc., established in 2018, is a San Francisco-based company that specializes in live online leadership and management training. It offers a development platform that empowers organizations to enhance their employees' soft skills, including communication, team building, and conflict management. Hone's platform facilitates expert-led small group training, peer learning, and continuous reinforcement, while also providing data-driven insights to measure and improve training impact.
Founded in 2016, Latchel operates an online platform that streamlines maintenance coordination for property managers and landlords. Its platform enables tracking of maintenance requests, vendor selection, and mobile communication with tenants, aiming to increase net margins and renter satisfaction.
Spry is a digital health platform that enables movement health professionals to collect and analyze patient data in real time. By leveraging machine learning and artificial intelligence, the platform provides personalized protocols based on evidence-based practices and standards of care. This allows practitioners and owners of physical therapy centers to effectively manage both clinical and administrative functions, enhancing the quality of patient care and operational efficiency.
Immuneel Therapeutics
Series A in 2022
Immuneel Therapeutics specializes in developing innovative cell and gene therapies for cancer treatment. The company focuses on CAR-T cell therapies, which are created by extracting blood cells from patients and genetically engineering healthy immune cells to specifically target malignant cells. This approach allows cancer patients to benefit from advanced cell-based immunotherapies that have the potential to transform their treatment outcomes.
Founded in 2019, Vendr is a SaaS-based platform that streamlines software procurement for businesses. It offers services such as commercial negotiations, renewal management, and contract logistics to help companies efficiently manage their software purchases.
Proximie is a health technology company that enables surgeons worldwide to collaborate remotely using augmented reality, artificial intelligence, and machine learning. Its platform allows surgeons to visually guide complex surgeries, democratizing access to advanced surgical knowledge.
Peptone Ltd is a London-based company founded in 2016 that specializes in artificial intelligence solutions aimed at solving protein developability challenges within the biotechnology, biopharmaceutical, and life sciences sectors. The company offers a range of services, including antibody design and optimization, an extensive protein database, automated thermos-stability engineering, and the deployment of hybrid AI solutions. Its proprietary platform, CassandraAI, focuses on silico protein engineering, allowing for the efficient handling of complex tasks related to anomaly detection and failure risk assessment in protein development. By streamlining these processes, Peptone enables users to identify optimal pathways for therapeutic discovery, facilitating the generation of lab-quality molecules more swiftly and cost-effectively than traditional methods in the pharmaceutical industry.
CHARM Therapeutics
Series A in 2022
CHARM Therapeutics uses 3D deep learning and advanced drug discovery technologies to develop transformational medicines for diseases that are difficult to treat, aiming to enable clinicians to target undruggable disease targets with novel therapies that offer potentially life-changing efficacy.
Teleo specializes in transforming existing heavy machinery into remote-controlled robots, allowing operators to control equipment from a significant distance. By retrofitting current fleets with its advanced supervised autonomy technology, Teleo enables operators to seamlessly switch between machines and job sites, enhancing both productivity and safety. The company's approach allows machine operators to work from remote operation centers rather than being confined to the equipment's cabin, ultimately improving operational efficiency and providing valuable insights into job site conditions.
SpectrumAi
Seed Round in 2022
SpectrumAi is a digital health company focused on enhancing Autism care by increasing access to high-quality Applied Behavior Analysis (ABA) therapy for children globally. By collaborating with industry experts in technology and healthcare, as well as clinical leaders, parents, and payers, SpectrumAi aims to modernize the delivery of autism care. The company's innovative healthcare technology offers objective data, meaningful insights, and actionable recommendations, all designed to support patients in achieving optimal outcomes. These outcomes include fostering independent living, building meaningful relationships, pursuing lifelong vocational goals, and promoting self-advocacy. Through its efforts, SpectrumAi seeks to transform the landscape of autism treatment and improve the quality of life for individuals on the spectrum.